Communities of practice
Leishmania parasites are named after W.B. Leishman, who developed one of the earliest stains of Leishmania in 1901. Widespread in 22 countries in the New World and in 66 nations in the Old World, leishmaniasis is not found in South-east Asia. Human infections are found in 16 countries in Europe, including France, Italy, Greece, Malta, Spain and Portugal. Occurring in several forms, the disease is generally recognized for its cutaneous form which causes non-fatal, disfiguring lesions, although epidemics of the potentially fatal visceral form cause thousands of deaths.
2 Jun 2010
When interventions are planned, insufficient thought is given as to whether the poorest and most vulnerable members of society will benefit, according to the findings of a new review of the evidence. The reviewers call for more research to assess which infectious disease programmes benefit the poor and to identify the mechanisms that determine “pro-poor effectiveness”.
31 May 2010
Treating patients with visceral leishmaniasis in the Indian subcontinent: the evidence from clinical trials
A review of trials concludes that three drugs are of overall benefit, despite their side effects. Most research has been conducted in India; more must be done to confirm which drugs work best in Bangladesh and Nepal and to bring effective treatment to patients in all three countries.
18 Nov 2010
What is the place for research in global efforts to control neglected tropical diseases?
16 Nov 2010
Scientists interested in research on neglected protozoan diseases were recently given an opportunity to hear presentations from leaders in the field, and to consider the emerging findings and progress of eight major research projects.
24 Feb 2011
The latest G-FINDER report says that funding for basic scientific research has increased but finances available for product development have fallen. How can funders determine where the greatest needs lie and work more closely together?
28 Jan 2011
Three-quarters of the patients given the drug miltefosine were cured of their infection, compared with only half of those on the standard treatment.
20 May 2010
So far in the 21st century (and with the exception of malaria and AIDS), only four new products have become available for treating or preventing infections in poor communities.
18 Dec 2009
The global budget for research into the infectious diseases of poverty is little changed and AIDS continues to receive a disproportionately large share of the total. But India and Brazil are emerging as key players, particular for the more neglected diseases.
23 Dec 2008
Is your organisation working against the infectious diseases of poverty?